Prescription Medicines
Linac Inj.
- Product Category
- Nonsteroidal anti-inflammatory painkillers
- Active Ingredients
- Diclofenac Sodium
- Appearance
- An injection containing a colorless or light yellow transparent liquid in a brown transparent ampoule.
- Reimbursement Code
- 648100421
01 / 02
1. Composition and Strength : In 1 ampoule (2mL)
- Active ingredient: Diclofenac sodium (USP)----75mg
- Stabilizer: dry sodium sulfite (KP)----6mg
Sodium edetate hydrate (KP)----3mg
- Additives: Lidocaine hydrochloride hydrate, Macrogol 300, sodium hydroxide, water for injection, propylene glycol
2. Effectiveness
It can be used for the following diseases:
Rheumatoid arthritis, osteoarthritis (degenerative joint disease), ankylosing spondylitis,
Post-surgical/post-traumatic inflammation and pain, acute gout, renal and hepatic colic
3. Dosage and dosage
• Adults: Inject 75 mg (1 ampoule) of diclofenac sodium deeply into the upper side of the buttocks once a day.
In severe cases, 75 mg (1 ampoule) at a time can be administered twice a day, and in this case, the injection is alternately administered to both sides of the buttocks.
After the initial treatment, administration should be changed to tablets or suppositories.
Increase or decrease appropriately depending on age, disease, and symptoms.
To minimize cardiovascular adverse reactions from this drug, the lowest effective dose should be used for the shortest period of time.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about signs and/or symptoms of serious cardiovascular toxicity and what measures to take if these symptoms occur.
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered. Nonsteroidal anti-inflammatory drugs (NSAIDs), including this drug, may be associated with an increased risk of gastrointestinal anastomotic leak. Close medical surveillance and caution are recommended when using this drug after gastrointestinal surgery.
4) Hypersensitivity reactions may progress to Kounis syndrome (allergic vasospastic angina/allergic myocardial infarction), a serious allergic reaction that can cause myocardial infarction. Symptoms of this reaction may include chest pain that may be associated with an allergic reaction to this drug.
5) Ampoule injections may contain glass fragments when cutting the container, which may cause adverse reactions. When using, cut carefully to minimize glass fragments, but be especially careful when using them on children and the elderly.
2. Do not administer to the following patients
1) Peptic ulcer patients
2) Patients with severe blood abnormalities
3) Patients with severe liver impairment
4) Patients with severe renal impairment
5) Patients with severe high blood pressure
6) Patients with severe cardiac dysfunction
7) Patients with hypersensitivity to the ingredients of this drug
8) Patients with a history of asthma, urticaria, or other allergic reactions due to this drug, aspirin, or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactoid reactions have been rarely reported after administration of non-steroidal anti-inflammatory drugs.)
9) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
10) Patients with congestive heart failure (NYHA levels 2 to 4), ischemic heart disease, peripheral artery disease, and/or cerebrovascular disease
3. Administer with caution to the following patients:
1) Patients with a history of peptic ulcer
2) Patients with blood abnormalities or a history thereof
3) Patients with hepatic impairment, renal impairment or their history
4) Patients with high blood pressure
5) Patients with cardiac dysfunction
6) SLE (systemic lupus erythematosus) patients and mixed connective tissue disease (MCTD) patients
7) Patients with a history of hypersensitivity
8) Patients with bronchial asthma
9) Patients with ulcerative colitis
10) Patients with Crohn’s disease
11) Elderly people, children, infants
12) This drug contains sodium sulfite, which may cause allergies such as anaphylaxis, and may cause life-threatening or milder asthma attacks in some susceptible patients. The overall frequency of sulfite sensitivity in the general population is unknown, but appears to be low, and sulfite sensitivity appears to be more frequent in asthmatics than in non-asthmatic patients.
4. Adverse reactions
1) Shock: In rare cases, shock symptoms (symptoms of shock, coldness, difficulty breathing, paralysis of the extremities, decreased blood pressure, edema, rash, itching, etc.) may appear. In such cases, stop administration and take appropriate measures.
2) Digestive system: In rare cases, peptic ulcer, gastrointestinal bleeding, esophageal ulcer, or perforation may occur. In such cases, discontinue administration.
3) Blood: In rare cases, granulocytosis, hemoglobin, leukocyte, thrombocytopenia, anemia, aplastic anemia, hemolytic anemia, bleeding tendency, purpura, allergic purpura, etc. may occur.
4) Skin: In rare cases, Stevens-Johnson syndrome (mucocutaneous ocular syndrome), Riel syndrome (toxic epidermal necrosis), photosensitivity, redness, itching, eczema, dermatitis, angioedema, erythema multiforme, flushing, and exudative dermatitis may occur. In such cases, discontinue administration and take appropriate measures.
5) Liver: In rare cases, hepatitis, jaundice, liver failure, and elevated GOT/GPT may occur. Be especially careful when coadministering with contraindications.
6) Kidney: In rare cases, acute renal failure may occur. If oliguria, hematuria, increased urine protein, BUN, blood creatinine, hyperkalemia, etc. occur, discontinue administration immediately and take appropriate measures.
7) Hypersensitivity: In rare cases, asthma attacks, sometimes rashes, hives, etc. may occur. In such cases, discontinue administration and take appropriate measures.
8) Mental nervous system: As aseptic meningitis has been rarely reported, if symptoms such as severe headache, nausea, vomiting, insomnia, stiff neck, fever, or impaired consciousness appear, immediately discontinue administration and consult a doctor. In particular, administer with caution to patients with autoimmune diseases (SLE, MCTD). Additionally, insomnia, depression, irritability, anxiety, and double vision may occur. In rare cases, headache, drowsiness, dizziness, nervousness, paralysis, confusion, hallucinations, and convulsions may occur.
9) Sensory system: In rare cases, blurred vision, tinnitus, transient pain, dryness, itchiness, and superficial keratitis may occur.
10) Circulatory system: In rare cases, increased blood pressure, decreased blood pressure, palpitations, tachycardia, congestive heart failure, ventricular extrasystoles, myocardial infarction, etc. may occur. Kounis syndrome (allergic vasospastic angina/allergic myocardial infarction) has also been reported with unknown frequency. Through clinical trials and epidemiological studies, there have been reports that long-term administration of diclofenac, especially at high doses (150 mg per day), may be associated with an increased risk of arterial thrombosis (e.g. myocardial infarction or stroke) (see ‘2. Do not administer to the following patients’ and ‘5. General precautions’).
11) Respiratory system: Occasionally, epistaxis, asthma, pharyngeal edema, interstitial pneumonia, etc. may occur.
12) Urinary system: Frequent urination, enuresis, erectile dysfunction, and vaginal bleeding may occur.
13) Others: Occasionally, edema, rare malaise, sweating, etc. may occur.
14) As a result of analysis and evaluation of clue information based on adverse event reporting data after drug marketing (1989-June 2017), the newly confirmed adverse events are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
• Skin and subcutaneous tissue system-DRESS syndrome
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) When using for chronic diseases, consider the following:
① Patients taking this drug for a long period of time should regularly conduct clinical tests (urinalysis, blood tests such as complete blood count (CBC) and physicochemical tests, liver function tests, etc.), and if abnormalities are found, take appropriate measures such as reducing the dose or stopping the medication. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
② Consider treatments other than drug therapy.
4) When using for acute diseases, consider the following:
① Administer considering the degree of acute inflammation, pain, and fever.
② In principle, long-term administration of the same drug should be avoided.
③ If there is a causative treatment, implement it.
5) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions. Symptoms of excessive decrease in body temperature, collapse, and cooling of extremities may occur, so pay special attention to the patient's condition after administration, especially in the case of children, infants, the elderly, and patients with consumptive diseases with high fever.
6) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
7) Hypertension: Non-steroidal anti-inflammatory drugs, including this drug, may cause hypertension or worsen existing hypertension, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
8) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
9) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, renal dysfunction, liver dysfunction, patients taking diuretics or ACE inhibitors, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
10) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
11) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g. eosinophilia, rash) appear, administration of this drug should be discontinued.
12) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
13) Anaphylactoid reaction: Anaphylactic reaction, such as swelling of the eyelids, lips, pharynx, and larynx, hives, asthma, bronchospasm, and decreased blood pressure, can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactoid reaction occurs, emergency treatment must be administered.
14) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which may be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
15) Drug reaction with increased eosinophilia and systemic symptoms (DRESS syndrome): Drug reaction with increased eosinophils and systemic symptoms (DRESS syndrome) has been reported in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). Some of these cases were fatal or life-threatening. DRESS syndrome is usually, but not always, accompanied by fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, and myositis. Sometimes the symptoms of DRESS syndrome may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not mentioned here may be involved. It is important to note that early symptoms of hypersensitivity, such as fever or lymphadenopathy, may appear even if the rash is not evident. If these signs or symptoms occur, this drug should be discontinued immediately and the patient evaluated.
16) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
17) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroids may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
18) Due to the pharmacological properties of this drug, it may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
19) Patients with important risk factors related to cardiovascular disease (e.g. high blood pressure, hyperlipidemia, diabetes, smoking) should be treated with this drug after careful review.
20) The cardiovascular risk of this drug may increase depending on the dose and exposure period, so it should be administered at the lowest effective dose for the shortest possible period. The patient's needs for symptom relief and response to treatment should be reassessed regularly.
6. Interaction
1) Do not use in combination with other non-steroidal anti-inflammatory drugs (NSAIDs) as the risk of adverse reactions may increase.
2) When administered in combination with digoxin, its action may be enhanced, so administer with caution, such as reducing the amount of the drug.
3) When administered concurrently with corticosteroids, mutual adverse reactions may increase.
4) Since the antihypertensive effect of ACE inhibitors, angiotensin receptor antagonists, and beta blockers may be reduced by nonsteroidal anti-inflammatory drugs, such interactions should be kept in mind when administered together. When NSAIDs and ACE inhibitors or angiotensin receptor antagonists are coadministered to the elderly, volume-depleted patients (including those taking diuretics), or patients with reduced renal function, a deterioration of renal function, such as reversible acute renal failure, may occur. After starting this combination treatment, renal function should be monitored regularly, and the patient should be provided with adequate fluids.
5) Furosemide and thiazide diuretics
① As a result of clinical trials and post-marketing surveillance, it was confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidney. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
② When administered in combination with furosemide, its effect may be reduced.
6) Aspirin
① There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
② When administered in combination with aspirin, its effectiveness may be reduced.
7) Lithium: Non-steroidal anti-inflammatory drugs can enhance the action of lithium by increasing serum lithium concentration and reducing renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when co-administering non-steroidal anti-inflammatory drugs and lithium, carefully observe signs of lithium toxicity and reduce the dose if necessary.
8) Methotrexate: Concurrent administration with nonsteroidal anti-inflammatory drugs (NSAIDs) delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered in combination with high doses of methotrexate used in anticancer therapy, and must be administered with caution when administered in combination with low doses of methotrexate.
9) Coumarin anticoagulants (warfarin, etc.): Warfarin and non-steroidal anti-inflammatory analgesics may have a synergistic effect on gastrointestinal bleeding. Patients who use the two drugs together may have a higher risk of bleeding compared to when administered alone, so sufficient observation, including blood coagulation ability tests, is required when coadministered with a coumarin-based anticoagulant.
10) When NSAIDs and cyclosporine are administered together, the nephrotoxicity of cyclosporine may increase, so renal function should be monitored during combined administration.
11) Co-administration of this drug with other non-steroidal anti-inflammatory drugs or salicylates increases the risk of gastrointestinal toxicity, so co-administration is not recommended.
12) When this drug and pemetrexed are administered together, the risk of bone marrow suppression, kidney and gastrointestinal toxicity may increase. Patients with renal impairment and creatinine clearance of 45-79 mL/min should be monitored for myelosuppression, renal and gastrointestinal toxicity during co-administration of this drug and pemetrexed. For non-steroidal anti-inflammatory drugs with a short elimination half-life (e.g., diclofenac, indomethacin), it is recommended to temporarily discontinue administration for 2 days before, on the day of, and 2 days after administration of pemetrexed. In the absence of data regarding a potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), it is recommended that patients taking pemetrexed temporarily discontinue pemetrexed for at least 5 days before, on the day of, and up to 2 days after administration of pemetrexed.
7. Administration to pregnant women
1) There is no clinical data on administering this drug to pregnant women. Administration of this drug at the end of pregnancy may cause premature closure of the ductus arteriosus and fetal circulatory failure (PFC), so this drug should be avoided in pregnant women (especially at the end of pregnancy).
2) Use of non-steroidal anti-inflammatory drugs (NSAIDs), including this drug, after approximately 20 weeks of pregnancy may cause abnormalities in fetal renal function, resulting in oligohydramnios and, in some cases, neonatal renal failure. Although oligohydramnios has been uncommonly reported within 48 hours of starting nonsteroidal anti-inflammatory drugs (NSAIDs), this side effect usually appears days to weeks after administration. Oligohydramnios is usually reversible upon discontinuation of treatment, but this is not always the case. If oligohydramnios persists, complications (e.g., limb contractures and delayed lung maturation) may occur. Some post-marketing cases of impaired neonatal renal function have required invasive procedures such as exchange transfusion or dialysis. If administration of this drug is necessary during the 20th to 30th week of pregnancy, the lowest effective dose should be used for the shortest period of time and if the administration time exceeds 48 hours, ultrasound monitoring of amniotic fluid should be considered. If oligohydramnios occurs, discontinue this drug and follow-up according to medical guidelines.
3) In an experiment in which it was administered to rats in the late stages of pregnancy, constriction of the ductus arteriosus in the fetus was reported.
4) In experiments on rats, non-steroidal anti-inflammatory drugs, like other drugs that inhibit prostaglandin synthesis, increased the frequency of dystocia, delayed delivery, and decreased the survival rate of pups.
5) Since safety for pregnant women has not been established, it should be administered to women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
6) Non-steroidal anti-inflammatory drugs may interfere with or delay follicular rupture due to their prostaglandin-mediated mechanism of action, which may cause reversible infertility in some women. Therefore, women who have difficulty conceiving or are undergoing infertility tests should consider discontinuing the use of non-steroidal anti-inflammatory drugs, including this drug.
8. Administration to nursing mothers
Transfer into breast milk has been reported, and there is concern that serious adverse reactions may occur in infants due to this. Therefore, considering the importance of drug administration to nursing mothers, breastfeeding or drug administration should be discontinued.
9. Administration to newborns and infants
1) Newborns and infants generally have imperfect body temperature control mechanisms, so there is a possibility that excessive body temperature decreases due to administration. Therefore, it is administered to newborns and infants when they have diseases such as excessive body temperature rise.
2) Safety for children has not been established. In children, administer with caution at the minimum necessary dose and pay particular attention to the occurrence of adverse reactions.
10. Administration to elderly people
In elderly patients, administer with caution at the minimum necessary dose and pay particular attention to the occurrence of adverse reactions.
11. Overdose
1) Signs and symptoms: Information on overdose is lacking, and typical clinical symptoms have not been established.
2) Treatment: In case of overdose due to non-steroidal anti-inflammatory drugs, the following treatment is usually administered.
- Provide symptomatic treatment for low blood pressure, renal failure, convulsions, gastrointestinal disorders, and respiratory depression.
- When the protein binding rate is high, forced diuresis and hemodialysis are not useful for removal of diclofenac.
5. How to save
Light-proof sealed container, stored at room temperature (1-30℃)
6. Packaging unit
2mL × 50Amp
7. Expiration date
36 months from date of manufacture
- Active ingredient: Diclofenac sodium (USP)----75mg
- Stabilizer: dry sodium sulfite (KP)----6mg
Sodium edetate hydrate (KP)----3mg
- Additives: Lidocaine hydrochloride hydrate, Macrogol 300, sodium hydroxide, water for injection, propylene glycol
2. Effectiveness
It can be used for the following diseases:
Rheumatoid arthritis, osteoarthritis (degenerative joint disease), ankylosing spondylitis,
Post-surgical/post-traumatic inflammation and pain, acute gout, renal and hepatic colic
3. Dosage and dosage
• Adults: Inject 75 mg (1 ampoule) of diclofenac sodium deeply into the upper side of the buttocks once a day.
In severe cases, 75 mg (1 ampoule) at a time can be administered twice a day, and in this case, the injection is alternately administered to both sides of the buttocks.
After the initial treatment, administration should be changed to tablets or suppositories.
Increase or decrease appropriately depending on age, disease, and symptoms.
To minimize cardiovascular adverse reactions from this drug, the lowest effective dose should be used for the shortest period of time.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about signs and/or symptoms of serious cardiovascular toxicity and what measures to take if these symptoms occur.
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered. Nonsteroidal anti-inflammatory drugs (NSAIDs), including this drug, may be associated with an increased risk of gastrointestinal anastomotic leak. Close medical surveillance and caution are recommended when using this drug after gastrointestinal surgery.
4) Hypersensitivity reactions may progress to Kounis syndrome (allergic vasospastic angina/allergic myocardial infarction), a serious allergic reaction that can cause myocardial infarction. Symptoms of this reaction may include chest pain that may be associated with an allergic reaction to this drug.
5) Ampoule injections may contain glass fragments when cutting the container, which may cause adverse reactions. When using, cut carefully to minimize glass fragments, but be especially careful when using them on children and the elderly.
2. Do not administer to the following patients
1) Peptic ulcer patients
2) Patients with severe blood abnormalities
3) Patients with severe liver impairment
4) Patients with severe renal impairment
5) Patients with severe high blood pressure
6) Patients with severe cardiac dysfunction
7) Patients with hypersensitivity to the ingredients of this drug
8) Patients with a history of asthma, urticaria, or other allergic reactions due to this drug, aspirin, or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactoid reactions have been rarely reported after administration of non-steroidal anti-inflammatory drugs.)
9) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
10) Patients with congestive heart failure (NYHA levels 2 to 4), ischemic heart disease, peripheral artery disease, and/or cerebrovascular disease
3. Administer with caution to the following patients:
1) Patients with a history of peptic ulcer
2) Patients with blood abnormalities or a history thereof
3) Patients with hepatic impairment, renal impairment or their history
4) Patients with high blood pressure
5) Patients with cardiac dysfunction
6) SLE (systemic lupus erythematosus) patients and mixed connective tissue disease (MCTD) patients
7) Patients with a history of hypersensitivity
8) Patients with bronchial asthma
9) Patients with ulcerative colitis
10) Patients with Crohn’s disease
11) Elderly people, children, infants
12) This drug contains sodium sulfite, which may cause allergies such as anaphylaxis, and may cause life-threatening or milder asthma attacks in some susceptible patients. The overall frequency of sulfite sensitivity in the general population is unknown, but appears to be low, and sulfite sensitivity appears to be more frequent in asthmatics than in non-asthmatic patients.
4. Adverse reactions
1) Shock: In rare cases, shock symptoms (symptoms of shock, coldness, difficulty breathing, paralysis of the extremities, decreased blood pressure, edema, rash, itching, etc.) may appear. In such cases, stop administration and take appropriate measures.
2) Digestive system: In rare cases, peptic ulcer, gastrointestinal bleeding, esophageal ulcer, or perforation may occur. In such cases, discontinue administration.
3) Blood: In rare cases, granulocytosis, hemoglobin, leukocyte, thrombocytopenia, anemia, aplastic anemia, hemolytic anemia, bleeding tendency, purpura, allergic purpura, etc. may occur.
4) Skin: In rare cases, Stevens-Johnson syndrome (mucocutaneous ocular syndrome), Riel syndrome (toxic epidermal necrosis), photosensitivity, redness, itching, eczema, dermatitis, angioedema, erythema multiforme, flushing, and exudative dermatitis may occur. In such cases, discontinue administration and take appropriate measures.
5) Liver: In rare cases, hepatitis, jaundice, liver failure, and elevated GOT/GPT may occur. Be especially careful when coadministering with contraindications.
6) Kidney: In rare cases, acute renal failure may occur. If oliguria, hematuria, increased urine protein, BUN, blood creatinine, hyperkalemia, etc. occur, discontinue administration immediately and take appropriate measures.
7) Hypersensitivity: In rare cases, asthma attacks, sometimes rashes, hives, etc. may occur. In such cases, discontinue administration and take appropriate measures.
8) Mental nervous system: As aseptic meningitis has been rarely reported, if symptoms such as severe headache, nausea, vomiting, insomnia, stiff neck, fever, or impaired consciousness appear, immediately discontinue administration and consult a doctor. In particular, administer with caution to patients with autoimmune diseases (SLE, MCTD). Additionally, insomnia, depression, irritability, anxiety, and double vision may occur. In rare cases, headache, drowsiness, dizziness, nervousness, paralysis, confusion, hallucinations, and convulsions may occur.
9) Sensory system: In rare cases, blurred vision, tinnitus, transient pain, dryness, itchiness, and superficial keratitis may occur.
10) Circulatory system: In rare cases, increased blood pressure, decreased blood pressure, palpitations, tachycardia, congestive heart failure, ventricular extrasystoles, myocardial infarction, etc. may occur. Kounis syndrome (allergic vasospastic angina/allergic myocardial infarction) has also been reported with unknown frequency. Through clinical trials and epidemiological studies, there have been reports that long-term administration of diclofenac, especially at high doses (150 mg per day), may be associated with an increased risk of arterial thrombosis (e.g. myocardial infarction or stroke) (see ‘2. Do not administer to the following patients’ and ‘5. General precautions’).
11) Respiratory system: Occasionally, epistaxis, asthma, pharyngeal edema, interstitial pneumonia, etc. may occur.
12) Urinary system: Frequent urination, enuresis, erectile dysfunction, and vaginal bleeding may occur.
13) Others: Occasionally, edema, rare malaise, sweating, etc. may occur.
14) As a result of analysis and evaluation of clue information based on adverse event reporting data after drug marketing (1989-June 2017), the newly confirmed adverse events are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
• Skin and subcutaneous tissue system-DRESS syndrome
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) When using for chronic diseases, consider the following:
① Patients taking this drug for a long period of time should regularly conduct clinical tests (urinalysis, blood tests such as complete blood count (CBC) and physicochemical tests, liver function tests, etc.), and if abnormalities are found, take appropriate measures such as reducing the dose or stopping the medication. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
② Consider treatments other than drug therapy.
4) When using for acute diseases, consider the following:
① Administer considering the degree of acute inflammation, pain, and fever.
② In principle, long-term administration of the same drug should be avoided.
③ If there is a causative treatment, implement it.
5) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions. Symptoms of excessive decrease in body temperature, collapse, and cooling of extremities may occur, so pay special attention to the patient's condition after administration, especially in the case of children, infants, the elderly, and patients with consumptive diseases with high fever.
6) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
7) Hypertension: Non-steroidal anti-inflammatory drugs, including this drug, may cause hypertension or worsen existing hypertension, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
8) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
9) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, renal dysfunction, liver dysfunction, patients taking diuretics or ACE inhibitors, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
10) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
11) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g. eosinophilia, rash) appear, administration of this drug should be discontinued.
12) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
13) Anaphylactoid reaction: Anaphylactic reaction, such as swelling of the eyelids, lips, pharynx, and larynx, hives, asthma, bronchospasm, and decreased blood pressure, can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactoid reaction occurs, emergency treatment must be administered.
14) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which may be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
15) Drug reaction with increased eosinophilia and systemic symptoms (DRESS syndrome): Drug reaction with increased eosinophils and systemic symptoms (DRESS syndrome) has been reported in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). Some of these cases were fatal or life-threatening. DRESS syndrome is usually, but not always, accompanied by fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, and myositis. Sometimes the symptoms of DRESS syndrome may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not mentioned here may be involved. It is important to note that early symptoms of hypersensitivity, such as fever or lymphadenopathy, may appear even if the rash is not evident. If these signs or symptoms occur, this drug should be discontinued immediately and the patient evaluated.
16) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
17) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroids may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
18) Due to the pharmacological properties of this drug, it may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
19) Patients with important risk factors related to cardiovascular disease (e.g. high blood pressure, hyperlipidemia, diabetes, smoking) should be treated with this drug after careful review.
20) The cardiovascular risk of this drug may increase depending on the dose and exposure period, so it should be administered at the lowest effective dose for the shortest possible period. The patient's needs for symptom relief and response to treatment should be reassessed regularly.
6. Interaction
1) Do not use in combination with other non-steroidal anti-inflammatory drugs (NSAIDs) as the risk of adverse reactions may increase.
2) When administered in combination with digoxin, its action may be enhanced, so administer with caution, such as reducing the amount of the drug.
3) When administered concurrently with corticosteroids, mutual adverse reactions may increase.
4) Since the antihypertensive effect of ACE inhibitors, angiotensin receptor antagonists, and beta blockers may be reduced by nonsteroidal anti-inflammatory drugs, such interactions should be kept in mind when administered together. When NSAIDs and ACE inhibitors or angiotensin receptor antagonists are coadministered to the elderly, volume-depleted patients (including those taking diuretics), or patients with reduced renal function, a deterioration of renal function, such as reversible acute renal failure, may occur. After starting this combination treatment, renal function should be monitored regularly, and the patient should be provided with adequate fluids.
5) Furosemide and thiazide diuretics
① As a result of clinical trials and post-marketing surveillance, it was confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidney. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
② When administered in combination with furosemide, its effect may be reduced.
6) Aspirin
① There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
② When administered in combination with aspirin, its effectiveness may be reduced.
7) Lithium: Non-steroidal anti-inflammatory drugs can enhance the action of lithium by increasing serum lithium concentration and reducing renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when co-administering non-steroidal anti-inflammatory drugs and lithium, carefully observe signs of lithium toxicity and reduce the dose if necessary.
8) Methotrexate: Concurrent administration with nonsteroidal anti-inflammatory drugs (NSAIDs) delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered in combination with high doses of methotrexate used in anticancer therapy, and must be administered with caution when administered in combination with low doses of methotrexate.
9) Coumarin anticoagulants (warfarin, etc.): Warfarin and non-steroidal anti-inflammatory analgesics may have a synergistic effect on gastrointestinal bleeding. Patients who use the two drugs together may have a higher risk of bleeding compared to when administered alone, so sufficient observation, including blood coagulation ability tests, is required when coadministered with a coumarin-based anticoagulant.
10) When NSAIDs and cyclosporine are administered together, the nephrotoxicity of cyclosporine may increase, so renal function should be monitored during combined administration.
11) Co-administration of this drug with other non-steroidal anti-inflammatory drugs or salicylates increases the risk of gastrointestinal toxicity, so co-administration is not recommended.
12) When this drug and pemetrexed are administered together, the risk of bone marrow suppression, kidney and gastrointestinal toxicity may increase. Patients with renal impairment and creatinine clearance of 45-79 mL/min should be monitored for myelosuppression, renal and gastrointestinal toxicity during co-administration of this drug and pemetrexed. For non-steroidal anti-inflammatory drugs with a short elimination half-life (e.g., diclofenac, indomethacin), it is recommended to temporarily discontinue administration for 2 days before, on the day of, and 2 days after administration of pemetrexed. In the absence of data regarding a potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), it is recommended that patients taking pemetrexed temporarily discontinue pemetrexed for at least 5 days before, on the day of, and up to 2 days after administration of pemetrexed.
7. Administration to pregnant women
1) There is no clinical data on administering this drug to pregnant women. Administration of this drug at the end of pregnancy may cause premature closure of the ductus arteriosus and fetal circulatory failure (PFC), so this drug should be avoided in pregnant women (especially at the end of pregnancy).
2) Use of non-steroidal anti-inflammatory drugs (NSAIDs), including this drug, after approximately 20 weeks of pregnancy may cause abnormalities in fetal renal function, resulting in oligohydramnios and, in some cases, neonatal renal failure. Although oligohydramnios has been uncommonly reported within 48 hours of starting nonsteroidal anti-inflammatory drugs (NSAIDs), this side effect usually appears days to weeks after administration. Oligohydramnios is usually reversible upon discontinuation of treatment, but this is not always the case. If oligohydramnios persists, complications (e.g., limb contractures and delayed lung maturation) may occur. Some post-marketing cases of impaired neonatal renal function have required invasive procedures such as exchange transfusion or dialysis. If administration of this drug is necessary during the 20th to 30th week of pregnancy, the lowest effective dose should be used for the shortest period of time and if the administration time exceeds 48 hours, ultrasound monitoring of amniotic fluid should be considered. If oligohydramnios occurs, discontinue this drug and follow-up according to medical guidelines.
3) In an experiment in which it was administered to rats in the late stages of pregnancy, constriction of the ductus arteriosus in the fetus was reported.
4) In experiments on rats, non-steroidal anti-inflammatory drugs, like other drugs that inhibit prostaglandin synthesis, increased the frequency of dystocia, delayed delivery, and decreased the survival rate of pups.
5) Since safety for pregnant women has not been established, it should be administered to women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
6) Non-steroidal anti-inflammatory drugs may interfere with or delay follicular rupture due to their prostaglandin-mediated mechanism of action, which may cause reversible infertility in some women. Therefore, women who have difficulty conceiving or are undergoing infertility tests should consider discontinuing the use of non-steroidal anti-inflammatory drugs, including this drug.
8. Administration to nursing mothers
Transfer into breast milk has been reported, and there is concern that serious adverse reactions may occur in infants due to this. Therefore, considering the importance of drug administration to nursing mothers, breastfeeding or drug administration should be discontinued.
9. Administration to newborns and infants
1) Newborns and infants generally have imperfect body temperature control mechanisms, so there is a possibility that excessive body temperature decreases due to administration. Therefore, it is administered to newborns and infants when they have diseases such as excessive body temperature rise.
2) Safety for children has not been established. In children, administer with caution at the minimum necessary dose and pay particular attention to the occurrence of adverse reactions.
10. Administration to elderly people
In elderly patients, administer with caution at the minimum necessary dose and pay particular attention to the occurrence of adverse reactions.
11. Overdose
1) Signs and symptoms: Information on overdose is lacking, and typical clinical symptoms have not been established.
2) Treatment: In case of overdose due to non-steroidal anti-inflammatory drugs, the following treatment is usually administered.
- Provide symptomatic treatment for low blood pressure, renal failure, convulsions, gastrointestinal disorders, and respiratory depression.
- When the protein binding rate is high, forced diuresis and hemodialysis are not useful for removal of diclofenac.
5. How to save
Light-proof sealed container, stored at room temperature (1-30℃)
6. Packaging unit
2mL × 50Amp
7. Expiration date
36 months from date of manufacture
Product Updates
Total 7items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 7 | Linac Inj. | Precautions for use | 2025.04.15 | PDFLinakju_200201872_Precautions for use.pdf |
| 6 | Linac Inj. | Precautions for use | 2024.05.22 | PDFPermit changes (draft)_Rainakju.pdf |
| 5 | Linac Inj. | Precautions for use | 2023.08.19 | PDF0056_200201872_Precautions for use (Linakju).pdf |
| 4 | Linac Inj. | Precautions for use | 2022.03.31 | PDF44_200201872_Precautions for use (Linakju) (final version).pdf |
| 3 | Linac Inj. | Precautions for use | 2020.02.29 | PDF0039_200201872_Precautions for use (Linakju) - Change instructions (2020.01.29).pdf |
| 2 | Linac Inj. | Precautions for use | 2018.12.24 | PDF0036_200201872_Precautions for use_Linakju.pdf |
| 1 | Linac Inj. | Linakju (dosage, precautions for use) | 2014.12.22 | HWPLinakju Usage Dosage_Precautions for Use_1.hwp |